OncLive TV

Dr. Philip on Treatment Challenges for Patients With Soft Tissue Sarcoma

June 20th 2016

Tony Philip, MD, medical oncologist, Monter Cancer Center of the North Shore-LIJ Cancer Institute, assistant professor of Medicine, Hofstra-North Shore LIJ School of Medicine and NYIT College of Osteopathic Medicine, discusses treatment challenges for patients with soft tissue sarcoma.

Dr. Mark Kris on Immunotherapy and Frontline Options for Patients With NSCLC

June 18th 2016

Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, explains what community oncologists need to know regarding immunotherapy and frontline treatment options for patients with non–small cell lung cancer (NSCLC).

Dr. Christian Gisselbrecht on Outcomes of Relapsed DLBCL

June 17th 2016

Christian Gisselbrecht, MD, a Professor of Haematology in the Haemato-Oncology Department of Hôpital Saint-Louis, at Diderot University, Paris, discusses refractory disease in aggressive diffuse large b-cell lymphoma (DLBCL).

Dr. Ahn on Link Between Tumor Somatic Variants and Chemo Resistance in Biliary Tract Cancer

June 16th 2016

Daniel H. Ahn, MD, assistant professor of Medicine, Mayo Clinic, discusses a next-generation sequencing survey of biliary track cancer to reveal the association between tumor somatic variants and chemotherapy resistance.

Jerome Galon on the Prognostic Value of Immunoscore

June 16th 2016

Jerome Galon, PhD, research director, Institut National de la Santé et de la Recherche Médicale, discusses the prognostic value of the Immunoscore assay and its corresponding validation study, which was presented during the 2016 ASCO Annual Meeting.

Dr. Overman on Nivolumab and Ipilimumab in Patients With MSI-H CRC

June 15th 2016

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses a study examining nivolumab (Opdivo) monotherapy, ipilimumab (Yervoy) monotherapy, and the combination of nivolumab and ipilimumab in patients with high microsatellite instability metastatic colorectal cancer.

Dr. Planchard on Dabrafenib/Trametinib Combo in Advanced NSCLC

June 15th 2016

David Planchard, MD, PhD, Department of Medical Oncology, Thoracic Unit, Institut Gustave Roussy, discusses a phase II trial examining the combination of dabrafenib and trametinib in pretreated patients with BRAF V600E-mutant advanced non–small cell lung cancer (NSCLC).

Dr. Rafii on Durvalumab in Patients With Urothelial Bladder Cancer

June 14th 2016

Saeed Rafii, MD, PhD, medical director, Sarah Cannon Research Institute, United Kingdom, discusses a phase I/II dose-escalation study examining the efficacy and safety of the PD-1 antibody durvalumab in patients with metastatic urothelial bladder cancer.

Dr. Jeffrey Weber on CheckMate-064 Trial for Advanced Melanoma

June 13th 2016

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program, Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, discusses the design and results of the CheckMate-064 trial, which examined outcomes in patients who received nivolumab (Opdivo) given sequentially with ipilimumab (Yervoy) in patients with advanced melanoma.

Dr. Sandra Demaria on Radiation and Immunotherapy Combination Regimens

June 10th 2016

Sandra Demaria, MD, assistant professor of Radiation Oncology, (Interim), Radiation Oncology, Weill Cornell Medical College and New-York Presbyterian, discusses the synergy with radiation therapy and immunotherapy as a potential combination regimen for patients with cancer.

Dr. Melissa Johnson on Atezolizumab in Patients With NSCLC

June 10th 2016

Melissa Johnson, MD, associate director, Lung Cancer Research, Sarah Cannon Research Institute, discusses the phase II BIRCH study, which is examining atezolizumab (Tecentriq) in patients with PD-L1–positive locally advanced or metastatic non–small cell lung cancer (NSCLC).

Yardena Samuels on RASA2 as Prognostic Biomarker in Melanoma

June 7th 2016

Yardena Samuels, PhD, Tenured Associate Professor, Department of Moleular Cell Biology, the Weizmann Institute of Science, Israel, discuses her lab’s discovery of a potential prognostic biomarker in cutaneous sporadic melanoma.

Dr. Rastinehad on Transperineal Fusion Biopsy for Prostate Cancer Focal Therapy

June 3rd 2016

Art Rastinehad, DO, Director of Focal Therapy and Interventional Urologic Oncology, Mount Sinai Health System, discusses an electromagnetically (EM) tracked transperineal MR/US fusion-guided biopsy platform (tpFBx) for prostate cancer.

Dr. Madhav Dhodapkar on IMiD-based Combinations in Multiple Myeloma

June 2nd 2016

Dr. Michael Williams on Treating Subtypes of MCL

May 31st 2016

Michael E. Williams, MD, ScM, Byrd S. Leavell Professor of Medicine and Professor of Pathology, University of Virginia Health System, discusses personalized medicine in mantle cell lymphoma (MCL).

Dr. Scott Tagawa Discusses IMMU-132 in Patients With Urothelial Carcinoma

May 31st 2016

Scott T. Tagawa, MD, MS, assistant professor of Medicine, medical director, Genitourinary Oncology Research Program, assistant attending physician, New York-Presbyterian Hospital, discusses the antibody-drug conjugate IMMU-132 for the treatment of patients with metastatic platinum-resistant urothelial cancer.

Dr. Barbieri on SPOP Mutations in Prostate Cancer

May 31st 2016

Christopher E. Barbieri, MD, PhD, surgeon, researcher in prostate cancer genomics, Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine and New-York Presbyterian, discusses the implications of SPOP mutations in patients with prostate cancer.

Dr. Elias Jabbour on Blinatumomab for ALL

May 31st 2016

​Elias Jabbour, MD, associate professor, department of leukemia, division of cancer medicine, the University of Texas MD Anderson Cancer Center, discusses blinatumomab (Blincyto) for acute lymphocytic leukemia (ALL).

Dr. Wierda on Immunotherapy Agents for Patients With CLL

May 31st 2016

William G. Wierda, MD, PhD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses immunotherapy agents being explored in patients with chronic lymphocytic leukemia (CLL).

Dr. Pinheiro on Determinants of Cost in the Treatment of T1-T3 Oropharynx Cancer

May 27th 2016

A. Daniel Pinheiro, MD, physician, Otolaryngology, Mercy Clinic, discusses a study looking at the determinants of cost in the treatment of patients with T1 to T3 oropharynx cancer.